|1.||Faderl, Stefan: 22 articles (07/2015 - 03/2003)|
|2.||Gandhi, Varsha: 18 articles (06/2014 - 03/2003)|
|3.||Kantarjian, Hagop: 16 articles (07/2015 - 10/2003)|
|4.||Kantarjian, Hagop M: 14 articles (06/2014 - 03/2003)|
|5.||Jeha, Sima: 14 articles (12/2011 - 03/2003)|
|6.||Plunkett, William: 13 articles (06/2014 - 03/2003)|
|7.||Ravandi, Farhad: 12 articles (07/2015 - 07/2006)|
|8.||Jabbour, Elias: 11 articles (07/2015 - 07/2009)|
|9.||Garcia-Manero, Guillermo: 11 articles (07/2015 - 10/2003)|
|10.||Cortes, Jorge: 10 articles (07/2015 - 03/2003)|
09/01/2007 - "Clofarabine induced durable complete remission in heavily pretreated adolescents with relapsed and refractory leukemia."
12/01/2003 - "Induction of complete remission using single agent clofarabine in a patient with primary refractory acute myeloblaste leukemia."
12/01/2009 - "Recent clinical studies have established the efficacy of clofarabine in treating malignancies with a poor prognosis, such as adult, elderly, and relapsed pediatric leukemia. "
12/01/2013 - "Clofarabine is the most promising PNA in current clinical trials in pediatric and adult patients with acute leukemias. "
07/01/2011 - "Encouraging results of clinical trials with clofarabine in acute leukemias inclined to present background knowledge about multidirectional biomolecular mechanism of its cytotoxicity."
|2.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
04/01/2005 - "Clofarabine has proven to be effective in the treatment of adult and pediatric acute myelogenous leukemia (AML). "
06/01/2009 - "Clofarabine: a new treatment option for patients with acute myeloid leukemia."
12/01/2013 - "This Phase I, multicenter study assessed the maximum-tolerated dose, safety, pharmacokinetics and efficacy of clofarabine in Japanese adults with acute myeloid leukemia. "
05/01/2014 - "Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia."
12/01/2013 - "In Phase II studies from the USA and Europe, single-agent clofarabine demonstrated activity and acceptable toxicity in elderly patients with previously untreated acute myeloid leukemia. "
|3.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/01/2005 - "In 61 pediatric patients with relapsed or refractory acute lymphoblastic leukemia treated with clofarabine 52 mg/m2 infused intravenously over 2 hours once daily for 5 days every 2-6 weeks, rates of complete remission, complete remission without platelet recovery, and partial remission were 12%, 8%, and 10%, respectively. "
06/01/2013 - "Clofarabine is effective in the treatment of children with relapsed/refractory acute lymphoblastic leukemia and its adverse effects can be tolerated. "
06/01/2013 - "Clofarabine could be a promising new treatment for relapsed/refractory acute lymphoblastic leukemia."
12/01/2006 - "Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia."
04/20/2006 - "Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia."
|4.||B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
07/01/2006 - "Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment."
03/01/2003 - "Comparison of cytotoxicity of 2-chloro- 2'-arabino-fluoro-2'-deoxyadenosine (clofarabine) with cladribine in mononuclear cells from patients with acute myeloid and chronic lymphocytic leukemia."
11/01/2001 - "DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine."
07/01/2006 - "Based on its mechanistic similarity to fludarabine and cladribine and the success of these analogues for treatment of chronic lymphocytic leukemia (CLL), we hypothesized that clofarabine would be effective for indolent leukemias. "
09/01/1999 - "The objective of the present study was to investigate the biochemical pharmacology of 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine (CAFdA)--a fluorinated analogue of cladribine [2-chloro-2'-deoxyadenosine, Leustatin (CdA)] with improved acid and metabolic stability--in human leukemic cell lines and in mononuclear cells isolated from patients with chronic lymphocytic leukemia (CLL) and acute myelocytic leukemia (AML). "
02/01/2013 - "Here, we investigated the efficacy of the combined treatment of various phytochemicals with the anticancer drug clofarabine in malignant mesothelioma MSTO-211H cells and normal mesothelial MeT-5A cells. "
11/01/2014 - "Collectively, our data represent that the efficacy of resveratrol and clofarabine for apoptosis induction was substantially enhanced by Bcl-xL-lowering strategy in which the simultaneous targeting of Mcl-1 and Bcl-xL could be a more effective strategy for treating malignant mesothelioma. "
11/01/2014 - "In this study, we investigated whether inhibition of Bcl-xL influences cell growth and apoptosis against simultaneous treatment of resveratrol and clofarabine in the human malignant mesothelioma H-2452 cells. "
03/01/2015 - "We previously demonstrated that resveratrol and clofarabine elicited a marked cytotoxicity on malignant mesothelioma (MM) MSTO-211H cells but not on the corresponding normal mesothelial MeT-5A cells. "
11/01/2014 - "Knockdown of Bcl-xL enhances growth-inhibiting and apoptosis-inducing effects of resveratrol and clofarabine in malignant mesothelioma H-2452 cells."
|3.||Etoposide (VP 16)
|7.||Granulocyte Colony-Stimulating Factor (G-CSF)
|1.||Drug Therapy (Chemotherapy)
|3.||Hematopoietic Stem Cell Transplantation
|4.||Transplantation (Transplant Recipients)
|5.||Stem Cell Transplantation